MedTrace Logo

Comparison of Two Meningococcal ACWY Conjugate Vaccines

NCT01192997 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2020-10-01

No results posted yet for this study

Summary

There is evidence of waning immunity in individuals vaccinated against meningitis C as part of the UK infant immunisation schedule. The intention of this study is to contact participants of a previous NVEC (National Vaccine Evalutaion Consortium) clinical trial (a PreSchool Men C trial, in which participants were randomised to receive Meningitec, Menjugate or Neisvac-C). They will be invited to enrol and will be randomised to receive one of two quadrivalent meningococcal ACWY vaccines, to look at the boosting effect they may confer.

Conditions

  • Meningococcal Meningitis

Interventions

BIOLOGICAL

Menveo

Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).

BIOLOGICAL

MenACWY-TT

Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)

Sponsors & Collaborators

  • Public Health England

    lead OTHER_GOV

Principal Investigators

  • Elizabeth Miller, MD · Public Health England

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-10-31
Completion
2014-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01192997 on ClinicalTrials.gov